<DOC>
	<DOCNO>NCT01893125</DOCNO>
	<brief_summary>To investigate effect repeat oral dose CNV2197944 75 mg tid pain experience diabetic peripheral neuropathy ( DPN ) measure change PI-NRS three week treatment compare baseline period .</brief_summary>
	<brief_title>Efficacy Safety CNV2197944 Versus Placebo Patients With Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description>A 3 week randomise crossover study investigate effect repeat oral dose CNV2197944 75 mg tid versus placebo pain experience diabetic peripheral neuropathy ( DPN ) . Each 3 week treatment period seperated 2 week washout period . The primary outcome measure change baseline PI-NRS three week treatment . Secondary outcome measure include pain responder rate , clinical patient global impression pain , Neuropathic Pain Symptom Inventory .</detailed_description>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<criteria>Male female 18 85 year age inclusive , time signing informed consent Diabetes Mellitus ( Type I II ) HbA1c &lt; 9 % Evidence symmetrical bilateral pain low limbs evidence decrease sensation impaired reflex Michigan Neuropathy Screening Instrument score &gt; 3 physical examination Patients diabetic peripheral neuropathy ( DPN ) pain screen present 6 month . The maximum duration DPN longer 5 year Patients severe pain , may impair selfassessment pain due DPN Patients receive nerve block neuropathic pain within 4 week Patients concomitant medication use relieve pain DPN Patients documented failure respond maximally tolerate dose regimen gabapentin pregabalin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>